Induction of bimodal programmed cell death in malignant cells by the derivative Ukrain (NSC-631570).

Drugs Exp Clin Res

Faculty of Medicine, Memorial University, St. John's, Newfoundland, Canada.

Published: February 1997

Selective induction of malignant cell death is one of the major goals of effective and safe chemotherapy. Recent developments in the understanding of programmed cell death (PCD) or apoptosis are expected to provide new leads for a safer chemotherapy. The authors investigated whether the semisynthetic alkaloid thiophosphoric acid derivative Ukrain (NSC-631570) could induce PCD or apoptosis in human K562 leukaemia cells. Results showed that Ukrain induced two distinct modalities of cell death programmes. One modality corresponded morphologically to classical apoptosis or PCD characterized by blebbing and shedding of membrane vesicles with concomitant 51Cr release; however, the Ukrain-induced apoptosis was not associated with the characteristic nuclear DNA fragmentation. Higher concentrations of Ukrain induced a second cell death programme characterized by cell surface blister formation, high specific 51Cr release and extensive DNA polyploidy. These two cell death programmes are distinct from each other in that they are interphased by a silent period characterized by normal cell morphology and reduced specific 51Cr release.

Download full-text PDF

Source

Publication Analysis

Top Keywords

cell death
24
51cr release
12
cell
8
programmed cell
8
derivative ukrain
8
ukrain nsc-631570
8
pcd apoptosis
8
ukrain induced
8
death programmes
8
specific 51cr
8

Similar Publications

Background: Ubiquitination and deubiquitination are involved in the progression of human diseases, including acute pneumonia. In this study, we aimed to explore the functions of ubiquitin-specific peptidase 9X-linked (USP9X) in lipopolysaccharide (LPS)-treated WI-38 cells. Methods: WI-38 cells were treated with LPS to induce the cellular damage and inflammation.

View Article and Find Full Text PDF

Cell fate decisions, such as proliferation, differentiation, and death, are driven by complex molecular interactions and signaling cascades. While significant progress has been made in understanding the molecular determinants of these processes, historically, cell fate transitions were identified through light microscopy that focused on changes in cell morphology and function. Modern techniques have shifted towards probing molecular effectors to quantify these transitions, offering more precise quantification and mechanistic understanding.

View Article and Find Full Text PDF

Importance: Three similar phase 3 randomized clinical trials have investigated PD-1/PD-L1 (programmed cell death 1 protein/programmed cell death 1 ligand 1) inhibitors in combination with platinum-based chemotherapy vs chemotherapy alone as first-line treatment for advanced urothelial carcinoma (IMvigor130, atezolizumab; KEYNOTE-361, pembrolizumab; and CheckMate901, nivolumab). Only CheckMate901 reported overall survival (OS) benefit for the combination. The reason for these inconsistent results is unclear.

View Article and Find Full Text PDF

Immunomodulatory drug (IMiD) resistance is a key clinical challenge in myeloma treatment. Previous data suggests almost one third of myeloma patients acquire mutations in the key IMiD effector cereblon by the time they are pomalidomide refractory. Some events, including stop codons/frameshift mutations and copy loss, having clearly explicable effects on cereblon function.

View Article and Find Full Text PDF

Importance: Patients with transthyretin (ATTR) cardiac amyloid infiltration are increasingly diagnosed at earlier disease stages with no heart failure (HF) symptoms and a wide range of cardiac amyloid infiltration.

Objective: To characterize the clinical phenotype and natural history of asymptomatic patients with ATTR cardiac amyloid infiltration.

Design, Setting, And Participants: This cohort study analyzed data of all patients at 12 international centers for amyloidosis from January 1, 2008, through December 31, 2023.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!